Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies
Antibodies · 11.03.2024 · 13 (1) · 19
DOI: 10.3390/antib13010019 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 11.03.2024. Verfasst von Hannah V Giles und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2SY, UK. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Light chain measurements form an essential component of the testing strategy for the detection and monitoring of patients with suspected and/or proven plasma cell disorders. Urine-based electrophoretic assays remain at the centre of the international guidelines for response assessment but the supplementary role of serum-free light chain (FLC) assays in response assessment and the detection of disease progression due to their increased sensitivity has been increasingly recognised since their introduction in 2001. Serum FLC assays have also been shown to be prognostic across the spectrum of plasma cell disorders and are now incorporated into risk stratification scores for patients with monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma, and light chain amyloidosis (AL amyloidosis), as well as being incorporated into the criteria for defining symptomatic multiple myeloma. There are now multiple different commercially available serum FLC assays available with differing performance characteristics, which are discussed in this review, along with the implications of these for patient monitoring. Finally, newer methodologies for the identification and characterisation of monoclonal FLC, including modifications to electrophoretic techniques, mass spectrometry-based assays and Amylite, are also described along with the relevant published data available regarding the performance of each assay.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2SY, UK.
- Instute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK.
- Department of Clinical Haematology, University Hospitals North Midlands NHS Trust, Royal Stoke Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, UK.
- School of Medicine, Keele University, Keele, Newcastle-under-Lyme ST5 5BG, UK.
ORCID-Profile: Hannah V Giles, Kamaraj Karunanithi
Zitieren
APA
Giles, H. V., & Karunanithi, K. (2024). Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies. Antibodies, 13(1), 19. https://doi.org/10.3390/antib13010019
Vancouver
Giles HV, Karunanithi K. Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies. Antibodies. 2024;13(1):19. doi:10.3390/antib13010019
BibTeX
@article{Giles2024,
author = {Giles, Hannah V and Karunanithi, Kamaraj},
title = {Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies},
journal = {Antibodies},
year = {2024},
volume = {13},
number = {1},
pages = {19},
doi = {10.3390/antib13010019}
}
EUVIMED